Editor-in-Chief: Alex A. Adjei, MD, PhD, FACP
ISSN: 1556-0864
Online ISSN: 1556-1380
Frequency: 12 issues / year
Ranking: Oncology 26/202
Respiratory System 5/53
Impact Factor: 5.800
Editor's Choice

We highlight three articles on very different aspects of lung cancer in the July issue of the Journal. As investigators and clinicians in lung cancer know, the very useful 7th edition of the TNM classification for lung cancer is still based on anatomical information. The ongoing work by the IASLC staging committee, which will culminate in the publication of the 8th edition, is evaluating other prognostic markers including histology, tumor markers and molecular genetic factors. The first highlighted article is from the IASLC staging committee and is authored by Rami-Porta and colleagues. “The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer” discusses revisions of the T descriptors which will be included in the new edition of the TNM lung cancer classification. Hormone use and the risk of lung cancer in women continues to be an important area of research. Schwartz et al describes epidemiologic data on this subject in the article, “Hormone use, reproductive history and risk of lung cancer: the Women's Health Initiative Studies”. Finally, Koenig et al suggest that amplicon parallel sequencing improves the diagnostic accuracy of aberrant molecular events in NSCLC, in the article “Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients”. Alex A. Adjei, MD, PhD, Editor-in-Chief

Actions
View
  • Open Access
  • Free Access
  • Purchase Access
  • Partial Access
Actions
View
Login

Quick Poll

For coverage of this subject, please see Boland JM et al, J Thorac Oncol, 8: 574 -581, 2013

A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
 Submit
 Clear
 Results
Foreign Language Editions

JTO is proud to present translations of its content into French and Chinese. We sincerely thank  Jean-Louis Pujol, Wu Yilong, and Tony Mok for their work on the French and Chinese editions.  

French, Selected Articles

French JTO, Vol 1 Issue 1

French JTO, Vol 1 Issue 2

French JTO, Vol 1 Issue 3

 

Chinese, Selected Articles

Chinese JTO, Vol 2 Issue 2

 

Call for Videos
JTO accepts videos as supplemental content to articles. Submission guidelines online.
Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.